Visterra, Inc.: Series A $6M

Posted in I - Series A, Q - 3Q10, R - NORTH WEST, X - Antiviral, X - Influenza, X - Vaccines, XX - MA

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Apr

2010

Juvaris BioTherapeutics, Inc.: Series B $12.5M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Influenza, X - Leukemia, X - Vaccines, XX - CA

Juvaris BioTherapeutics (Burlingame, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing, bringing the total round to $25M. Participants include Kleiner Perkins Caufield & Byers, SV Life Sciences and an undisclosed corporate partner.

Mar

2010

Vaxart, Inc.: Series B $12.5M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Influenza, X - Toll Receptor, X - Vaccines, XX - CA

Vaxart (San Francisco, CA) a preclinical-stage developer of a platform vaccine technology focusing on oral delivery that leverages an adjuvant based upon a toll-like receptor, closed a $12.5M Series B financing. Participants include Care Capital.

Mar

2010

Immune Targeting Systems, Ltd.: Series A $13.2

Posted in I - Series A, Q - 1Q10, R - INTERNATIONAL, X - Immunology, X - Influenza, X - Vaccines

Immune Targeting Systems (United Kingdom) a clinical-stage biopharma focused on synthetic vaccines for seasonal influenza strains, closed a $13.2M Series A financing, bringing the total round to $20.2M. Participants include Novartis Venture Funds, HealthCap, Truffle Capital and London Technology Fund.

Jan

2010

Pulmatrix, Inc.: Series B $30.2M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Nov

2009

Juvaris BioTherapeutics, Inc.: Series B $12.5M*

Posted in I - Series B, Q - 3Q09, R - WEST, X - Influenza, X - Leukemia, X - Vaccines, X - Veterinary, XX - CA

Juvaris BioTherapeutics (Pleasanton, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing. Participants include SV Life Sciences and Kleiner Perkins Caufield & Byers.

*Estimated first close of round

Oct

2009

Adamas Pharmaceuticals, Inc.: Series D $40M

Posted in I - Series D, Q - 3Q09, R - WEST, X - Antiinfective, X - CNS, X - Dementia, X - Influenza, X - Parkinson's, XX - CA

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Aug

2009

Zosano Pharma, Inc.: Series B $30M

Posted in I - Series B, Q - 3Q09, R - WEST, X - Device (Delivery), X - Influenza, X - Osteoporosis, XX - CA

Zosano Pharma (Fremont, CA) a clinical-stage device company focused on a transdermal microprojection delivery system for needle-free administration therapeutic peptides, small molecules and vaccines. Participants include Nomura Phase4 Ventures, New Enterprise Associates, HBM BioVentures and ProQuest Investments.

May

2009

Parasol Therapeutics, Inc.: Series A $3.25M

Posted in I - Series A, Q - 2Q09, R - NORTH EAST, X - Device (Diagnostic), X - Influenza, X - Vaccines, XX - MA

Parasol Therapeutics (Cambridge, MA) a seed-stage company focused on treatments and diagnostics for influenza, closed a $3.3M Series A financing. Participants include Polaris Venture Partners, Flagship Ventures and Lux Capital.

Feb

2009

HX Diagnostics, Inc.: Series A $3.1M

Posted in I - Series A, Q - 1Q09, R - WEST, X - Device (Diagnostic), X - Influenza, XX - CA

HX Diagnostics (Emeryville, CA) an early-stage diagnostics company developing seasonal and pandemic influenza assays, closed a $3.1M Series A financing. Participants include Kleiner Perkins Caufield & Byers, Nanogen and Xiamen YST Biotech.

to top of page...